MedTrace Logo

A Pilot Study of Additional Chinese Formula for Concurrent Chemoradiotherapy in Oral Cavity Cancer Patients

NCT05590650 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2022-10-26

No results posted yet for this study

Summary

The goal of this clinical trial is to learn about the clinical efficacy of San-Zhong-Kui-Jian-Tang (SZKJT), a formula of Chinese medicine in head and neck cancer patients receiving concurrent chemoradiotherapy (CCRT) treatments. The main questions it aims to answer are:

* Can SZKJT improve the completion rate of CCRT?
* Can SZKJT reduce the adverse effects of CCRT?
* How SZKJT affect the quality of life in the patients receiving CCRT
* How about the safety of using SZKJT in the patients receiving CCRT

Participants will be asked to:

* take SZKJT for 9 weeks during the whole CCRT course
* take questionnaires of quality of life

Conditions

  • Head and Neck Neoplasm
  • Chemoradiotherapy

Interventions

DRUG

SZKJT(San-Zhong-Kui-Jian-Tang)

The SZKJT samples were made and packed by Kaiser Pharmaceutical Co. Ltd. with lot number of 2019023247.

Sponsors & Collaborators

  • China Medical University Hospital

    lead OTHER

Principal Investigators

  • Ming-Yu Lien, Ph.D · China Medical University Hospital

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-07
Primary Completion
2020-06-14
Completion
2020-12-25

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05590650 on ClinicalTrials.gov